Sangui Biotech International, Inc. (SGBI)

[funnyG986]

SGBI great news unnoticed 0.02 x 0.03

http://www.finanznachrichten.de/nachrichten-2016-12/39507407-dgap-news-sangui-biotech-international-inc-sastomed-schliesst-vertriebsvereinbarung-fuer-die-tuerkei-granulox-erhaelt-produktzulassung-in-kuwe-016.htm


DGAP-News: Sangui BioTech International Inc. / Key word (s): Miscellaneous Sangui BioTech International Inc .: - SastoMed signs distribution agreement for Turkey; - Granulox receives product approval in Kuwait

21.12.2016 / 10:43 The issuer is solely responsible for the content of this announcement.

Sangui BioTech: - SastoMed signs distribution agreement for Turkey

- Compulsory fixed-dose quantity agreed - Granulox receives product approval in Kuwait

Witten, 21.12.2016:

Following the successful integration of the sales regions South East Asia and Russia in October this year, SastoMed GmbH, to which Sangui BioTech GmbH has licensed the worldwide distribution rights for the wound spray Granulox, has now also entered into a sales partnership with Turkey. With SAF Pharma Health Services SA (SAF), a powerful partner for the introduction of Granulox in this important territory was won. As was already the case with Zuellig Pharma for Southeast Asia and the MDP Group for Russia, it was also possible to agree with the SAF guaranteed fixed purchase rate for Turkey. In the course of the next five years, the SAF will, in line with the anticipated course of the approval and reimbursement procedure, obtain annually increasing minimum volumes with a total volume in the high five-digit range. "With Turkey, a further, promising sales region with 78 million inhabitants could be awarded to an ambitious partner. The fact that minimum sample sizes could be agreed again confirms our partners' trust in the successful market launch of Granulox," says Michael Sander , Managing Director of SastoMed GmbH.

In December, the product approval procedure for Granulox in Kuweit was successfully completed. The product approval is essential for a successful distribution of Granulox. Granulox was therefore approved for the first time in an Islamic state. "This approval makes it clear that the marketing of granulox is also possible in countries which, due to religious practices, have reservations about products containing porcine ingredients. The authorities have convinced and assisted on the ground in terms of clinical and health care "This is an important precedent that supports our efforts in other Muslim countries such as Indonesia," says Michel Sander.

Sangui BioTech International, Inc. ("SGBI") is a holding company whose shares are traded on OTCQB (www.otcmarkets.com: SGBI) and in the free circulation of the stock exchanges in Berlin and Hamburg-Hannover (www.boersenag.de: SBH) will. Its business purpose is to raise funds and secure access to the capital market for Sangui Group companies. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui Biotech International, Inc.

Further information: Sangui Biotech International, Inc. Thomas Striepe Fax: [phone] E-Mail: [e-mail]

Some statements in this release are forward-looking statements, estimates of future operating results or financial circumstances, or other forward-looking statements. Whether these statements are true depends on many known risks, unexpected developments, uncertainties or other factors that could lead to the fact that the future development actually deviates significantly from these future expectations. Forward-looking statements are based on a variety of variables and assumptions. A number of important risks that could lead to deviations from the statements made here include, but are not limited to, the ability of the company to obtain sufficient funding for future operations. Words such as "believe", "estimate", "plan", "expect", "intend" or "prediction", other forms of these words or comparable expressions are intended to indicate that these are forward-looking statements. The company does not assume any obligation beyond the statutory provisions to correct the statements made here or to adapt them to changed conditions and developments.

21.12.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer / publisher is responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements, Financial / Corporate News and Press Releases. Media archive at http://www.dgap.de

532201 21.12.2016

ISIN US80105B1017

AXC0065 2016-12-21 / 10: 44